The Goldman Sachs Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price raised by The Goldman Sachs Group from $36.00 to $45.00 in a research report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on TEVA. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Barclays boosted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Finally, Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.11.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $34.50 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $37.35. The firm has a market capitalization of $39.57 billion, a P/E ratio of 28.75, a PEG ratio of 1.98 and a beta of 0.70. The company’s fifty day moving average is $31.58 and its two-hundred day moving average is $24.05.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the business earned $0.71 earnings per share. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 77,400 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares in the company, valued at approximately $11,116,224. This represents a 17.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 422,060 shares of company stock worth $12,254,965. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Allworth Financial LP grew its position in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the period. Grove Bank & Trust boosted its stake in Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the period. Advisors Asset Management Inc. purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $41,000. Finally, Global Retirement Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.